Loading
A phase 2/3 trial of rozanolixizumab in childhood cancers, run by UCB Biopharma SRL, active and no longer recruiting.
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06149559 by UCB Biopharma SRL, with 14 participants enrolled, started 2024-06-14 and due to reach its primary completion in 2026-10-05. Interventions recorded: rozanolixizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares UCB, Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/